<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01550562</url>
  </required_header>
  <id_info>
    <org_study_id>A7002</org_study_id>
    <nct_id>NCT01550562</nct_id>
  </id_info>
  <brief_title>Effects of Programming Parameters on Back Pain Relief in Subthreshold Spinal Cord Stimulation</brief_title>
  <official_title>Precision™ High-Rate Sub-perception Spinal Cord Stimulation for the Treatment of Chronic Intractable Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of varying programming parameters in&#xD;
      subthreshold spinal cord stimulation therapy for pain relief.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    In &gt;9 months only 1 patient enrolled. Study stopped because design was too cumbersome and&#xD;
    subjects not willing to participate&#xD;
  </why_stopped>
  <start_date type="Actual">February 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Relief</measure>
    <time_frame>4,8,and 12 days post temporary lead(s) implantation</time_frame>
    <description>Mean within-patient difference in average back pain intensity among treatment groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Relief Responder Rate</measure>
    <time_frame>4,8,and 12 days post temporary lead(s) implantation</time_frame>
    <description>Difference in the proportion of subjects with ≥50% reduction in average back pain intensity among treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leg Pain Reduction</measure>
    <time_frame>4,8,and 12 days post temporary lead(s) implantation</time_frame>
    <description>Mean within-patient difference in average leg pain intensity among treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability</measure>
    <time_frame>4,8,and 12 days post temporary lead(s) implantation</time_frame>
    <description>Mean within-patient difference in disability among treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Pain Relief</measure>
    <time_frame>4,8,and 12 days post temporary lead(s) implantation</time_frame>
    <description>Mean within-patient difference in overall percent pain relief among treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life, as Measured by EQ-5D-5L</measure>
    <time_frame>4,8,and 12 days post temporary lead(s) implantation</time_frame>
    <description>Mean within-patient difference in quality of life among treatment groups</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Sham Stimulation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sham subthreshold spinal cord stimulation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subthreshold spinal cord stimulation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subthreshold spinal cord stimulation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Boston Scientific Precision Plus spinal cord stimulation therapy</intervention_name>
    <description>Epidural spinal cord stimulation (SCS) using the Boston Scientific Precision Plus SCS system</description>
    <arm_group_label>Sham Stimulation</arm_group_label>
    <arm_group_label>Treatment 1</arm_group_label>
    <arm_group_label>Treatment 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic intractable pain of the trunk and/or limbs&#xD;
&#xD;
          -  Documented history of trunk and/or limb pain of at least 180 days&#xD;
&#xD;
          -  Average back pain intensity of 5 or greater on a 0-10 numerical rating scale during&#xD;
             the 7-day period prior to the Screening Visit&#xD;
&#xD;
          -  Pass study site's routine psychological/psychiatric evaluation within 180 days of the&#xD;
             Trial Lead Insertion Visit&#xD;
&#xD;
          -  If taking any medications for chronic pain, must be on a stable prescription during&#xD;
             the 14-day period prior to the Trial Lead Insertion Visit and agree to continue on the&#xD;
             same prescription throughout study participation&#xD;
&#xD;
          -  Subject is willing and able to comply with all protocol-required procedures and&#xD;
             assessments/evaluations&#xD;
&#xD;
          -  Subject is able to independently read and complete all questionnaires and/or&#xD;
             assessments provided in English&#xD;
&#xD;
          -  18 years of age or older when written informed consent is obtained&#xD;
&#xD;
          -  Subject signs a valid, Ethics Committee-approved informed consent form (ICF) provided&#xD;
             in English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to operate the PrecisionPlus™ system&#xD;
&#xD;
          -  Primary source of pain is cancer-related, pelvic, visceral, angina, or migraine&#xD;
&#xD;
          -  Is a high surgical risk&#xD;
&#xD;
          -  Is diabetic&#xD;
&#xD;
          -  Is immunocompromised&#xD;
&#xD;
          -  Currently on any anticoagulant medications that cannot be discontinued during&#xD;
             perioperative period&#xD;
&#xD;
          -  Untreated major depression or untreated generalized anxiety disorder&#xD;
&#xD;
          -  Diagnosed with somatoform disorder, severe personality disorder, borderline&#xD;
             personality disorder&#xD;
&#xD;
          -  Diagnosed with any major psychiatric disorder not specifically listed in previous two&#xD;
             exclusion criterion&#xD;
&#xD;
          -  Currently diagnosed with cognitive impairment that would limit subject's ability to&#xD;
             discern differences in pain severity, complete a pain diary, perform wound care&#xD;
&#xD;
          -  Current abuse of alcohol or illicit drugs&#xD;
&#xD;
          -  Subject requires Magnetic Resonance Imaging (MRI) while implanted with lead(s).&#xD;
&#xD;
          -  Subject is participating (or intends to participate) in another investigational drug&#xD;
             or device clinical trial that may influence the data that will be collected for this&#xD;
             study&#xD;
&#xD;
          -  Subject has previously undergone a spinal cord stimulation trial or is already&#xD;
             implanted with an active implantable device(s) to treat their pain (IPGs, implantable&#xD;
             drug pump, etc) or pacemaker or implantable cardiac defibrillator&#xD;
&#xD;
          -  Patient is a woman who is not using adequate contraception, is pregnant or&#xD;
             breastfeeding or intends to become pregnant during the course of the study (a urine&#xD;
             pregnancy test must be performed within 28 days prior to the Trial Lead Insertion&#xD;
             Visit in women of child-bearing potential and the test result document)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kay Adair</last_name>
    <role>Study Director</role>
    <affiliation>Boston Scientific Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hunter Pain Clinic</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2292</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 15, 2012</study_first_submitted>
  <study_first_submitted_qc>March 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2012</study_first_posted>
  <results_first_submitted>March 31, 2021</results_first_submitted>
  <results_first_submitted_qc>March 31, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 29, 2021</results_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>1 subject was enrolled in this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Randomized</title>
          <description>Eligible patients who were randomized in a 1:1:1:1:1:1 ratio to one of the six sequences of three treatment groups (sham stimulation, subthreshold spinal cord stimulation therapy 1, and subthreshold spinal cord stimulation therapy 2).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention, 4 - 5 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention, 4 - 5 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Intervention, 4 - 5 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Randomized</title>
          <description>Eligible patients who were randomized in a 1:1:1:1:1:1 ratio to one of the six sequences of three treatment groups (sham stimulation, subthreshold spinal cord stimulation therapy 1, and subthreshold spinal cord stimulation therapy 2).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Relief</title>
        <description>Mean within-patient difference in average back pain intensity among treatment groups</description>
        <time_frame>4,8,and 12 days post temporary lead(s) implantation</time_frame>
        <population>No study data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized</title>
            <description>Eligible patients who were randomized in a 1:1:1:1:1:1 ratio to one of the six sequences of three treatment groups (sham stimulation, subthreshold spinal cord stimulation therapy 1, and subthreshold spinal cord stimulation therapy 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief</title>
          <description>Mean within-patient difference in average back pain intensity among treatment groups</description>
          <population>No study data are available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief Responder Rate</title>
        <description>Difference in the proportion of subjects with ≥50% reduction in average back pain intensity among treatment groups</description>
        <time_frame>4,8,and 12 days post temporary lead(s) implantation</time_frame>
        <population>No study data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized</title>
            <description>Eligible patients who were randomized in a 1:1:1:1:1:1 ratio to one of the six sequences of three treatment groups (sham stimulation, subthreshold spinal cord stimulation therapy 1, and subthreshold spinal cord stimulation therapy 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief Responder Rate</title>
          <description>Difference in the proportion of subjects with ≥50% reduction in average back pain intensity among treatment groups</description>
          <population>No study data are available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Leg Pain Reduction</title>
        <description>Mean within-patient difference in average leg pain intensity among treatment groups</description>
        <time_frame>4,8,and 12 days post temporary lead(s) implantation</time_frame>
        <population>No study data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized</title>
            <description>Eligible patients who were randomized in a 1:1:1:1:1:1 ratio to one of the six sequences of three treatment groups (sham stimulation, subthreshold spinal cord stimulation therapy 1, and subthreshold spinal cord stimulation therapy 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Leg Pain Reduction</title>
          <description>Mean within-patient difference in average leg pain intensity among treatment groups</description>
          <population>No study data are available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disability</title>
        <description>Mean within-patient difference in disability among treatment groups</description>
        <time_frame>4,8,and 12 days post temporary lead(s) implantation</time_frame>
        <population>No study data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized</title>
            <description>Eligible patients who were randomized in a 1:1:1:1:1:1 ratio to one of the six sequences of three treatment groups (sham stimulation, subthreshold spinal cord stimulation therapy 1, and subthreshold spinal cord stimulation therapy 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Disability</title>
          <description>Mean within-patient difference in disability among treatment groups</description>
          <population>No study data are available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Pain Relief</title>
        <description>Mean within-patient difference in overall percent pain relief among treatment groups</description>
        <time_frame>4,8,and 12 days post temporary lead(s) implantation</time_frame>
        <population>No study data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized</title>
            <description>Eligible patients who were randomized in a 1:1:1:1:1:1 ratio to one of the six sequences of three treatment groups (sham stimulation, subthreshold spinal cord stimulation therapy 1, and subthreshold spinal cord stimulation therapy 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Pain Relief</title>
          <description>Mean within-patient difference in overall percent pain relief among treatment groups</description>
          <population>No study data are available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life, as Measured by EQ-5D-5L</title>
        <description>Mean within-patient difference in quality of life among treatment groups</description>
        <time_frame>4,8,and 12 days post temporary lead(s) implantation</time_frame>
        <population>No study data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized</title>
            <description>Eligible patients who were randomized in a 1:1:1:1:1:1 ratio to one of the six sequences of three treatment groups (sham stimulation, subthreshold spinal cord stimulation therapy 1, and subthreshold spinal cord stimulation therapy 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life, as Measured by EQ-5D-5L</title>
          <description>Mean within-patient difference in quality of life among treatment groups</description>
          <population>No study data are available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>No study data are available</desc>
      <group_list>
        <group group_id="E1">
          <title>Randomized</title>
          <description>Eligible patients who were randomized in a 1:1:1:1:1:1 ratio to one of the six sequences of three treatment groups (sham stimulation, subthreshold spinal cord stimulation therapy 1, and subthreshold spinal cord stimulation therapy 2).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Clinical Research Sciences</name_or_title>
      <organization>Boston Scientific</organization>
      <phone>6619494350</phone>
      <email>roshini.jain@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

